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Introduction {#s1}
============

Colorectal cancer (CRC) is one of the most prevalent cancers in the world [@pone.0109150-Jemal1]. With high levels of incidence and mortality, CRC imposes a significant and potentially avoidable public health burden in most industrialized countries [@pone.0109150-Micheli1], including the United States, Australia and European countries [@pone.0109150-Jemal2]--[@pone.0109150-Ananda1]. In China, CRC has attracted increasing attention over recent years, taking a second and fourth position in the incidence and mortality lists respectively among all malignant tumors in urban populations [@pone.0109150-Zhao1]. The National Plan for Cancer Prevention and Control in China (2004--2010) identified CRC as one of the highest priorities for intervention [@pone.0109150-the1].

CRC is characterized by high prevalence, a long asymptomatic period and eminently treatable precancerous lesions, which together suggests that screening is a prudent option. It has been reported in the literature that CRC screening can reduce mortality effectively and even curb incidence as a consequence of polyp removal [@pone.0109150-Pignone1].

There are several protocols already in existence regarding population CRC screening: the most common interventions being Faecal Occult Blood Test (FOBT), flexible sigmoidoscopy, and colonoscopy. The effectiveness of FOBT has been established by randomized clinical trials [@pone.0109150-Towler1], and population-based screening using FOBT can reduce mortality by one third [@pone.0109150-Kronborg1], [@pone.0109150-Mandel1]. The European Community and United State Multi-Society Task Force on CRC recommend an annual FOBT as one of multiple options for screening individuals at average risk of CRC [@pone.0109150-Winawer1], [@pone.0109150-Arbyn1]. The Asia Pacific Working Group Consensus Guideline (APWGCG) recommends FOBT as the first choice for CRC screening in resource-limited countries [@pone.0109150-Sung1]. However, using FOBT alone as a screening instrument may fail to detect lesions due to intermittent bleeding from CRC and precancerous polyps or in circumstances where small colorectal neoplasia have little or no tendency for bleeding.

Based on a series of CRC screening efficacy studies [@pone.0109150-Zheng1]--[@pone.0109150-Chen1], the Ministry of Health of China proposed a two-step protocol for population-based CRC screening: (1) an initial FOBT and high-risk factor questionnaire (HRFQ) followed by (2) a full colonoscopy for those suspected cases identified from the initial screening [@pone.0109150-Dong1]. Arguably, the choice of CRC screening protocols in resource limited settings should be predicated upon evidence of cost-effectiveness considering a wide range of factors such as sensitivity, specificity, acceptability, feasibility, affordability, compliance, and clinical capacity. Many countries such as the USA, Australia, Europe and some Asian countries have sought economic evaluation of their chosen screening protocols for CRC [@pone.0109150-LansdorpVogelaar1]. To our knowledge no such study in mainland China has yet been reported to date (despite extensive enquiry).

In this study, we evaluated the cost-effectiveness of two different CRC initial screening strategies (FOBT vs FOBT+HRFQ) using the Markov model.

Materials and Methods {#s2}
=====================

Ethics Statement {#s2a}
----------------

This study was approved by the Institutional Review Board of Clinical Research, the Second Affiliated Hospital, Zhejiang University School of Medicine, and was completed in accordance with the ethical principles of the declaration of Helsinki. Written informed consent was sought and obtained from participants prior to the study.

Study Design {#s2b}
------------

Data for this study came from the project "Comparison and Evaluation of Screening Programs for Colorectal Cancer in Urban Communities in China" (CESP) and published literature. The CESP project was undertaken from July 2006 to December 2008. A total of 400,000 urban residents aged from 40 to 74 years in Hangzhou, Shanghai and Harbin were approached by their local CDC (Center for Disease Control and Prevention) officials, who explained the study to them in detail. Those who agreed to participate in the study were asked to take a FOBT test and fill in a HRFQ. Individuals having one or more of the following features were identified as "risk positive" by the HRFQ: (1) first-degree relative(s) with CRC; (2) a personal history of cancers or intestinal polyps; (3) two or more of the symptoms/histories: (3a) chronic diarrhea; (3b) chronic constipation; (3c) mucous and bloody stool; (3d) history of appendicitis or appendectomy; (3e) history of chronic cholecystitis or cholecystectomy; (3f) history of psychological trauma (e.g. divorce, death of relatives). The participants with either a positive FOBT or a positive HRFQ were offered colonoscopic examination. Any polyps detected during the colonoscopy were removed immediately and sent for histological diagnosis by a pathologist. Those participants who had polyps removed were initially counselled and then followed up three years later with another colonoscopy. The "positive" participants without detected polyps had a second FOBT and HRFQ one year after the initial colonoscopy. Participants with a negative FOBT and those who did not undertake a FOBT screening or colonoscopy were monitored through a routine cancer registry system. Cancers diagnosed by medical facilities are reported to the cancer registry system.

CRC screening protocols tested in this study {#s2c}
--------------------------------------------

We compared two initial screening protocols: (1) FOBT alone and (2) FOBT plus HRFQ. In both protocols, individuals who were considered of interest were offered a colonoscopic examination.

1.  FOBT as an initial screening instrument

Four scenarios were developed for protocol one ([Figure S1](#pone.0109150.s001){ref-type="supplementary-material"}).

**Scenario A~1~**: The participants take a FOBT. Those with a FOBT positive result are offered a colonoscopy. Polyps (if found) are removed during the colonoscopic examination and follow-up colonoscopy is undertaken every three years for those with polyps removed. Those participants without polyps are offered another FOBT in ten years. Participants with an initial negative FOBT result or those having an initial positive FOBT but for whatever reasons elect not to comply with the recommended procedures were offered an annual follow-up FOBT.

**Scenario A~2~**: Similar to *Scenario A~1~*; however, those participants with an initial negative FOBT result or those having a positive FOBT initially but for whatever reasons elect not to comply with the recommended procedures were monitored through a routine cancer registry system.

**Scenario A~3~**: Similar to *Scenario A~1~*; however, those participants without polyps take part in an annual follow-up colonoscopy instead of a 10 year interval.

**Scenario A~4~**: Similar to *Scenario A~3~*; the only difference is that the participants with an initial negative FOBT result or those having a positive FOBT initially but for whatever reasons elect not to comply with the recommended procedures were monitored through a routine cancer registry system.

1.  FOBT plus HRFQ as an initial screening instrument

Four scenarios were developed for protocol two ([Figure S2](#pone.0109150.s002){ref-type="supplementary-material"}).

**Scenario B~1~** Participants are offered a FOBT and a HRFQ. Those resulting in a positive outcome (either FOBT or HRFQ) are offered a colonoscopic examination. The follow-up procedures are similar to those of *Scenario A~1~*.

**Scenario B~2~** Similar to *Scenario B~1~*; however, participants with an initial negative result(both FOBT and HRFQ)or those with a positive initial result but for whatever reasons elect not to comply with the recommended procedures were monitored through a routine cancer registry system.

**Scenario B~3~** Similar to *Scenario B~1~*; however, participants without polyps are offered an annual follow-up colonoscopy instead of a 10 years interval.

**Scenario B~4~** This is the scenario currently implemented in China. Participants are offered a FOBT and a HRFQ. Those with a positive result (either FOBT or HRFQ) are offered a colonoscopic examination. Polyps (if present) are removed during the colonoscopic examination and follow-up colonoscopy is undertaken every three years. Those without polyps take part in annual follow-up FOBT and HRFQ. The participants with a negative result(both FOBT and HRFQ)initially and those having a positive result initially but for whatever reasons elect not to comply with the recommended procedures were monitored through a routine cancer registry system.

Markov Model {#s2d}
------------

We estimated costs and effectiveness of these eight scenarios using the Markov model, a transitional probability model. The Markov model allows us to simulate the trajectory of a hypothetical cohort through different health states [@pone.0109150-Sonnenberg1]. A Markov model describes the probabilities of particular transitions of a particular group of people from one health state to another over a defined period of time. The health states are divided into transient states and absorbing states. A transient state can change to another transient state or to an absorbing state; whereas an absorbing state (such as death) cannot change to other states (such as normal, polyp, CRC) [@pone.0109150-Sonnenberg1]. We developed the Markov model using Microsoft Excel to simulate the progression of a cohort of 100,000 average-risk asymptomatic individuals moving through a defined series of states from 40 to 74 years. In this simulation, the health states of individuals were categorized either as normal, polyp, CRC or death. After successive iterations, the model estimated the cumulative costs and effectiveness for the entire cohort over a35 year period. Each resultant simulation was compared with that of a scenario in which no screening is involved.

Transitional Parameters {#s2e}
-----------------------

The simulation model was developed using Chinese population data. Some transitional parameters were borrowed from studies in other countries if they were not available in China.

The CESP project provided most of the clinical, epidemiological and costing data. It revealed that 45.37% and 53.22% eligible participants complied with the initial FOBT and FOBT+HRFQ requests respectively. Some 37.32% FOBT positive participants and 46.78% FOBT+HRFQ positive participants accepted the offer of colonoscopy. Every participant with polyps had polypectomy, amongst whom 32.07% resulted from FOBT screening alone, and 26.13% from FOBT+HRFQ screening. Previous studies showed that colonoscopic polypectomy can probably reduce CRC incidence by around 76--90% [@pone.0109150-Winawer2]. For this study, we assumed a conservative reduction of 75% CRC incidence following colonoscopic polypectomy. The sensitivity and specificity of FOBT were found to be 42.90% and 86.10%, respectively. The sensitivity of FOBT+HRFQ increased to 88.90%, while its specificity decreased to 71.70% [@pone.0109150-Liu1], [@pone.0109150-Zheng2]. The incidence and fatality data used in the simulation model came from the Chinese Cancer Registry Annual Reports [@pone.0109150-Zhao1] and the 5th National Census [@pone.0109150-Tabulation1] ([Table 1](#pone-0109150-t001){ref-type="table"}).

10.1371/journal.pone.0109150.t001

###### Parameters used for the modeling of CRC screening protocols.

![](pone.0109150.t001){#pone-0109150-t001-1}

  Variable                                                                      Values (range)                         Ref.
  -------------------------------------------------------------------------- -------------------- ----------------------------------------------
  Sensitivity of FOBT                                                         42.90% (20%--60%)    [@pone.0109150-Liu1], [@pone.0109150-Zheng2]
  Sensitivity of FOBT+HRFQ                                                    88.90% (75%--90%)    [@pone.0109150-Liu1], [@pone.0109150-Zheng2]
  Specificity of FOBT                                                         86.10% (50%--90%)    [@pone.0109150-Liu1], [@pone.0109150-Zheng2]
  Specificity of FOBT+HRFQ                                                    71.70% (50%--90%)    [@pone.0109150-Liu1], [@pone.0109150-Zheng2]
  Coverage of FOBT                                                            45.37% (30%--100%)                       CESP
  Compliance with colonoscopy request after initial screening by FOBT         37.32% (30%--100%)                       CESP
  Coverage of FOBT plus HRFQ                                                  53.22% (30%--100%)                       CESP
  Compliance with colonoscopy request after initial screening by FOBT+HRFQ    46.78% (30%--100%)                       CESP
  Polypectomy in people screened by FOBT                                            32.07%                             CESP
  Polypectomy in people screened by FOBT+HRFQ                                       26.13%                             CESP
  CRC prevented by colonoscopy                                                       75%                     [@pone.0109150-Winawer2]
  Discount rate                                                                  3% (0%--7%)                [@pone.0109150-Drummond1]
  Cost (Yuan)                                                                                     
  Marketing for FOBT                                                                  1                                CESP
  Marketing for FOBT+HRFQ                                                             1                                CESP
  Material of FOBT                                                                    5                                CESP
  Material of FOBT+HRFQ                                                               7                                CESP
  Distribution and return of FOBT                                                     3                                CESP
  Distribution and return of FOBT+HRFQ                                                3                                CESP
  Pathology                                                                          150                               BNHI
  Colonoscopy                                                                        290                               BNHI
  Polypectomy                                                                        500                               BNHI
  Treatment of CRC                                                                  41602                              BNHI

Note: CRC - Colorectal Cancer; FOBT - Faecal Occult Blood Test; HRFQ - High-Risk Factor Questionnaire; CESP - Comparison and Evaluation of Screening Programs for Colorectal Cancer in Urban Communities in China; BNHI -- Bureau of National Health Insurance.

Cost estimates {#s2f}
--------------

Only direct costs were estimated in this study by the third-party payer\'s perspective, which included costs associated with initial screening, colonoscopy, polypectomy, pathology tests, and treatment of CRC. The initial screening costs comprised expenses in marketing, materials and reagents for FOBT and HRFQ, and distribution and return of FOBT and HRFQ. These were calculated using the CESP data. All other costs were calculated based on the claim data of the Bureau of National Health Insurance (BNHI). All costs are expressed in Chinese Yuan in this paper and are inflated to the 2008 price level.

Effectiveness of CRC screening {#s2g}
------------------------------

The effectiveness of CRC screening was presented in terms of "Life Years" saved by the screening. It was calculated through estimating premature deaths (from 40 to 74 years old) as a result of CRC using an age-dependent formula for each age group. The "Life Years" saved under each screening scenario equals to the difference in life years lost between the tested screening scenario and the scenario without any screening. In this study, discount rates for both future costs and future life years were set at 3% [@pone.0109150-Drummond1].

Cost-effectiveness indicator {#s2h}
----------------------------

We used an Incremental cost-effectiveness ratio (ICER) to measure the cost-effectiveness of the tested screening protocols, defined as the "difference in costs divided by the corresponding difference in effectiveness". A smaller ICER indicates lower cost for saving one life year, reflecting improved cost-effectiveness.

Sensitivity analysis {#s2i}
--------------------

In the sensitivity analysis, we tested the impact of several parameters such as compliance, sensitivity, specificity, and discount rate on the robustness of the simulation model. One-way and two-way sensitivity analyses were applied to assess the influence of those parameters on ICER. The ranges of parameter variations were set as: FOBT - 30% to 100% for compliance; 20% to 60% for sensitivity; and 50% to 90% for specificity; FOBT plus HRFQ - 30% to 100% for compliance; 75% to 90% for sensitivity; and 50% to 90% for specificity; Colonoscopy - 30% to 100% for compliance; Discount rate - 0% to 7% ([Table 1](#pone-0109150-t001){ref-type="table"}).

Results {#s3}
=======

Costs {#s3a}
-----

When no screening was performed, the accumulated expenses over 35 years were estimated through 35 successive iterations in Markov modeling, which resulted in a total of 44,733,623 Yuan for 100,000 average-risk asymptomatic individuals aged 40 years. The total costs under the screening scenario would increase compared to that without screening, with *Scenario A~2~* having the lowest and *Scenario B~3~* having the highest costs. Nevertheless, CRC treatment costs were lower under all screening scenarios compared with those without screening ([Table 2](#pone-0109150-t002){ref-type="table"}).

10.1371/journal.pone.0109150.t002

###### Outcome of simulated Markov model for cost-effectiveness of CRC screening.

![](pone.0109150.t002){#pone-0109150-t002-2}

                                                  *No Screening*   *Scenario A~1~*   *Scenario A~2~*   *Scenario A~3~*   *Scenario A~4~*   *Scenario B~1~*   *Scenario B~2~*   *Scenario B~3~*   *Scenario B~4~*
  ---------------------------------------------- ---------------- ----------------- ----------------- ----------------- ----------------- ----------------- ----------------- ----------------- -----------------
  **Direct cost**                                                                                                                                                                               
  Marketing                                             0              790409             44570            889328             44828            777263             53234            1025147            53947
  Distribution and return of FOBT or FOBT+HRFQ          0              2371227           222852            2667985           224141            2371227           159703            3075442           161842
  Material of FOBT                                      0              3952045           133711            4446641           134485               0                 0                 0                 0
  Material of FOBT+HRFQ                                 0                 0                 0                 0                 0              5440842           372640            7176032           377631
  Pathology                                             0              2201185           124852            2476131           125575            3362131           231199            4432781           234295
  Colonoscopy                                           0             13269796           752667           14927305           757024           24876083           1710618          32797719           1733530
  Polypectomy                                           0              7337282           416173            8253770           418582           11207104           770663           14775938           780985
  Treatment of CRC                                   44733623         35998807          44343703          39542239          44676347          26796779          44103714          32732661          44502127
  Total                                              44733623         65920750          46038528          73203398          46380983          74791992          47401771          96015722          47844357
  △Cost                                                 0             21187127           1304905          28469775           1647359          30058369           2668148          51282098           3110734
  **Effectiveness**                                                                                                                                                                             
  Discounted life years lost, Yr                       9918             8033              9847              8765              9890              6030              9754              7251              9851
  Life years saved, Yr                                  0               1885               71               1153               28               3888               164              2667               67
  Life years saved, %                                   0               19.01             0.71              11.63             0.28              39.20             1.66              26.89             0.68
  CRC accumulated cases, N                             2131             1710              2123              1884              2129              1269              2115              1560              2127
  CRC deaths, N                                        1984             1593              1977              1754              1983              1182              1969              1452              1981
  CRC prevented, N                                      0                421                7                247                1                862               16                571                3
  CRC prevented, %                                      0               19.74             0.35              11.60             0.07              40.47             0.75              26.80             0.16
  △Effectiveness                                        0               1885               71               1153               28               3888               164              2667               67
  **ICER**                                              0               11236             18404             24689             59272             7732              16223             19227             46347

Note: CRC - Colorectal Cancer; FOBT - Faecal Occult Blood Test; HRFQ - High-Risk Factor Questionnaire; ICER - Incremental Cost-Effectiveness Ratio.

Effectiveness {#s3b}
-------------

The simulation identified 2131 cases of CRC when no screening was adopted, representing a loss of 9918 CRC-related discounted life years: screening prevents CRC and reduces the loss of CRC-related life years. The highest level of effectiveness was achieved under *Scenario B~1~*, which reduced 40.47% (862 cases) of CRC and avoided 39.20% of loss of CRC-related life years (3888 discounted life years) compared with those without screening ([Table 2](#pone-0109150-t002){ref-type="table"}).

Costs-effectiveness {#s3c}
-------------------

For every life year saved,7732 Yuan would be needed under *Scenario B~1~*, 11,236 Yuan under *Scenario A~1~*, 18,404 Yuan under *Scenario A~2~*, 24,689 Yuan under *Scenario A~3~*, 59,272 Yuan under *Scenario A~4~*, 16,223 Yuan under *Scenario B~2~*,19,227 Yuan under *Scenario B~3~*, and 46,347 Yuan under *Scenario B~4~*.*Scenario B~1~* is the most cost-effective protocol among all the scenarios.

Sensitivity analysis {#s3d}
--------------------

A greater change in ICER was found when colonoscopy request compliance increased compared with that when coverage of initial screening increased. Colonoscopy compliance also mediated the impact of initial screening coverage on ICER. ICER was more sensitive to changes in initial screening coverage when colonoscopy compliance was higher ([Table 3](#pone-0109150-t003){ref-type="table"}).

10.1371/journal.pone.0109150.t003

###### Impact of compliance of initial screening and colonoscopy request on ICER: two-way sensitivity analysis.

![](pone.0109150.t003){#pone-0109150-t003-3}

  Compliance with Colonoscopy    Range of coverage of initial screening   *Scenario A~1~*   *Scenario A~2~*   *Scenario A~3~*   *Scenario A~4~*   *Scenario B~1~*   *Scenario B~2~*   *Scenario B~3~*   *Scenario B~4~*
  ----------------------------- ---------------------------------------- ----------------- ----------------- ----------------- ----------------- ----------------- ----------------- ----------------- -----------------
  30%                                          30%--100%                   10819--10558      18794--18748      21654--21696      52882--52890       7504--7156       16238--16290      16843--16893      41307--41320
  50%                                          30%--100%                   11984--11247      17324--17501      29289--29395      68978--68923       8636--7916       15510--16044      24319--24449      57240--57138
  70%                                          30%--100%                   12599--11309      15396--15799      35276--35476      81265--80960       9071--8370       14177--15253      30271--30511      69725--69141
  100%                                         30%--100%                   13035--10883      12846--13562      42065--42467      93806--92387       9105--9518       12208--14167      37171--37631      83269--80430

Note: ICER - Incremental Cost-Effectiveness Ratio.

ICER decreased with rising sensitivity of initial screening. *Scenario A~3~* and *A~4~* were more sensitive to changes in FOBT sensitivity than *Scenario A~1~* and *A~2~*. When FOBT sensitivity surpassed 42.9% (the parameter used in the modeling), changes in ICER had slowed down dramatically. Moderate changes in ICER were found when the sensitivity of FOBT+HRFQ increased ([Figure 1](#pone-0109150-g001){ref-type="fig"}).

![ICER decreases with rising sensitivity of FOBT or FOBT+HRFQ: One-way sensitivity analysis.](pone.0109150.g001){#pone-0109150-g001}

Similarly, ICER decreased with rising specificity of initial screening. *Scenario A~3~* and *A~4~* were more sensitive to changes in specificity of initial screening than other scenarios. When the specificity of initial screening surpassed 86.1% for FOBT or 71.7% for FOBT+HRFQ (the parameters used in the modeling), changes in ICER had slowed down dramatically ([Figure 2](#pone-0109150-g002){ref-type="fig"}).

![ICER decreases with rising specificity of FOBT or FOBT+HRFQ: One-way sensitivity analysis.](pone.0109150.g002){#pone-0109150-g002}

ICER increased with rising discount rate. The ranking order of the eight scenarios in ICER remained largely unchanged with the increase of discount rate, except for *Scenario B~3~*. *Scenario B~3~*was less sensitive to rising discount rate than the others ([Figure 3](#pone-0109150-g003){ref-type="fig"}).

![ICER increases with discount rate: One-way sensitivity analysis.](pone.0109150.g003){#pone-0109150-g003}

*Scenario B~1~* proved to be the most cost-effective, regardless of how the above mentioned parameters changed.

Discussion {#s4}
==========

The Markov model simulation revealed that *Scenario B~1~* is the most cost-effective protocol for CRC screening, followed by *Scenario A~1~*, *B~2~*, *A~2~*, *B~3~*, *A~3~*, *B~4~*and *A~4~*. The cost per life year saved under *Scenario B~1~* is the lowest, regardless how simulation parameters were set or changed.

This finding indicates that a combined use of FOBT and HRFQ as an initial step for CRC screening is a better strategy than FOBT alone. Although this means an increase of costs, a greater level of effectiveness can be achieved. This study demonstrated that the costs of protocol two (FOBT+HRFQ as initial screening) under different scenarios are consistently higher than those of protocol one (FOBT as initial screening) under corresponding scenarios (i.e. *A~1~vsB~1~*, *A~2~vsB~2~*, *A~3~vsB~3~*, *A~4~vsB~4~*). However, the effectiveness of protocol two is consistently better than that of protocol one. In addition, regardless how simulation parameters were set or changed, the ICER of protocol two are always lower than those of protocol one.

For people having an initial negative screening result and those having a positive result but failing to comply with the recommended procedures, repeating the initial screening annually can produce a more cost-effective result than routine cancer registry only. This study showed that, for both protocol one and protocol two, scenarios with a repeated initial screening incurred greater costs consistently compared with their alternative counterparts requesting routine cancer registry only (*A~1~ vs A~2~*; *A~3~ vs A~4~*; *B~1~ vs B~2~*; *B~3~ vs B~4~*). However, the effectiveness and cost-effectiveness as measured by ICER of those scenarios with a repeated initial screening are consistently better than their alternative counterparts using routine cancer registry only.

For people having a negative colonoscopy result, a repeated colonoscopy every ten years can produce a more cost-effective result: annual colonoscopy is too expensive. The effectiveness and cost-effectiveness as measured by ICER for repeated colonoscopy at a ten-year interval are consistently better than those with annually repeated colonoscopy under corresponding scenarios (*A~1~ vs A~3~*; *A~2~ vs A~4~*; *B~1~ vs B~3~*; *B~2~ vs B~4~*).

Compliance rates have a significantly impact on the total cost and effectiveness of CRC screening programs. In previous studies, compliance rates for FOBT and colonoscopy were often estimated for modeling [@pone.0109150-Sonnenberg2]--[@pone.0109150-Tsoi1]. In this study, we built our models using real observational data. Meanwhile, we tested the impact of compliance rates on the models by varying the rates from 30% to 100%. We found that the compliance rates of our study participants are lower compared with findings undertaken elsewhere in China [@pone.0109150-Zheng3]. Zheng et al [@pone.0109150-Zheng3]achieved 87.4% coverage of FOBT+HRFQ screening and 76.6% compliance for colonoscopy requests in a rural Chinese population, significantly higher than those of this study population. However, under the preferred *Scenario B~1~*, the cost-effectiveness of the screening program would remain virtually unchanged if similar compliance rates were achieved in our study population because the increase of FOBT+HRFQ coverage would lead to a slight decrease of ICER; whereas, a slight increase of ICER would appear when compliance with colonoscopy increases.

It is unclear what contributed to the low compliance rates for CRC screening in our study population: further studies are warranted. Experiences of developed countries demonstrated that to reduce financial barriers and ensure equal access to those cancer screening programs are better financed by governments [@pone.0109150-Masseria1]--[@pone.0109150-Ascunce1]. Empirical evidence shows that improved understanding of CRC screening can encourage people to comply with prescribed procedures in screening programs [@pone.0109150-Cai1], [@pone.0109150-Meng1]. Unfortunately, CRC screening guidelines freely available to the public in some developed countries remain unavailable in China.

In China, cervical and breast cancer screening programs have been included in public health services for rural populations since 2009and a good cost-effectiveness has been presented[@pone.0109150-Shi1], [@pone.0109150-Canfell1].Based on evidence support of this study, we suggest that CRC screening be included in the public health services list.

Compared to previous studies, this study has some unique characteristics. It is worthy to note that the combined use of FOBT and HRFQ as initial screening for CRC is an original development in China. To our knowledge, this is the first study of its kind attempting to evaluate the cost-effectiveness of CRC screening programs in urban Chinese populations. The core data used for the simulation modeling came from real observational data.

Limitations {#s5}
===========

In this study, we only calculated direct costs. Indirect costs such as those associated with production loss due to attending screening and treatment services should be considered in future studies.

Conclusion {#s6}
==========

A combined use of FOBT and HRFQ is preferable in CRC screening programs as an initial screening instrument. Annual FOBT+HRFQ screening is recommended for those who have a negative initial result and those who have a positive result but have failed to comply with colonoscopy procedures. Repeated colonoscopy (for those with a positive result in initial screening but a negative colonoscopy result) should be performed at a ten-year interval instead of one-year.

The current Chinese Trial Version for CRC Screening Strategy falls into *Scenario B~4~*, which is one of the least cost-effective options and should be revised in line with *Scenario B~1~*.

Supporting Information {#s7}
======================

###### 

**Markov process for CRC screening protocol one (** ***Scenario A~1~--A~4~*** **) using FOBT as initial screening procedure.** Transitions to different Markov states (in oval) are described, with normal, polyp and CRC as transient states and death as an absorbing state (patients cannot leave). The parameters used in the model were described in [Table 1](#pone-0109150-t001){ref-type="table"}. Note: CRC - Colorectal Cancer; FOBT - Faecal Occult Blood Test; NC - No Compliance.

(TIF)

###### 

Click here for additional data file.

###### 

**Markov process for CRC screening protocol two (** ***Scenario B~1~--B~4~*** **) using FOBT+HRFQ as initial screening procedure.** Transitions to different Markov states (in oval) are described, with normal, polyp and CRC as transient states and death as an absorbing state (patients cannot leave). The parameters used in the model were described in [Table 1](#pone-0109150-t001){ref-type="table"}. Note: CRC - Colorectal Cancer; FOBT+HRFQ -Faecal Occult Blood Test + High-Risk Factor Questionnaire; NC - No Compliance.

(TIF)

###### 

Click here for additional data file.
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